Inolimomab

Inolimomab is a monoclonal antibody specifically designed for the treatment of acute graft-versus-host disease (aGVHD). It is a type of immunotherapy that targets the interleukin 2 (IL-2) receptor on the surface of activated T cells.

Mechanism of Action

Inolimomab works by binding to the IL-2 receptor on T cells. This prevents IL-2 from binding to its receptor, thereby inhibiting the activation and proliferation of T cells. This mechanism of action is particularly useful in the treatment of aGVHD, a condition in which donor T cells attack the recipient's body following a stem cell transplant.

Clinical Use

Inolimomab has been used in the treatment of steroid-resistant aGVHD. Clinical trials have shown that it can improve survival rates in patients with this condition. However, its use is associated with certain side effects, including infections and infusion reactions.

Regulatory Status

Inolimomab has been granted orphan drug status by the European Medicines Agency (EMA) for the treatment of aGVHD. This designation is given to drugs that treat rare diseases, providing certain benefits such as market exclusivity.

See Also

• Monoclonal antibodies
• Acute graft-versus-host disease
• Immunotherapy
• Interleukin 2
• T cells
• Stem cell transplant
• Orphan drug

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian